Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

JOHNSON & JOHNSON’s NEW CONSUMER SECTOR CHAIRMAN IS PETER LARSON

Executive Summary

JOHNSON & JOHNSON's NEW CONSUMER SECTOR CHAIRMAN IS PETER LARSON, succeeding Pierre Dupasquier, who is retiring, the company announced July 13. Larson's appointment to chairman of the Johnson & Johnson Consumer Sector Operating Committee is effective Aug. 1. He was also named a member of the J&J executive committee. Larson, 53, is currently a member of the consumer sector operating committee and group chairman for feminine hygiene and incontinence products in the consumer sector. Dupasquier, 61, will stay with the company through the end of the year to "help assure an orderly management transition," J&J said. Larson will report to J&J Chairman and CEO Ralph Larsen. In his new post, Larson will head up J&J's largest business with $8.8 bil. in 1991 revenues, or 36.8% of consolidated sales. Larson also will be responsible for the company's joint venture with Merck for OTC products. Consumer segment brands include Tylenol acetaminophen products, Johnson's baby toiletries, Act fluoride rinse, Sundown and Piz Buin sunscreens, Purpose acne therapy products and Band- Aid adhesive bandages. J&J-Merck products include the Mylanta antacid line. Edward Chase is president of J&J-Merck Pharmaceuticals. Larson joined J&J in 1967, starting in the information system division of the domestic operating company and moving up in the health care division through a series of marketing positions. Larson joined Kimberly-Clark in 1978 and was named president of the firm's health care sector before rejoining J&J in 1990 with his present title. Commenting on Dupasquier's retirement, company Chairman Ralph Larsen said the outgoing exec "has made a significant impact on the global development" of J&J's consumer business. Dupasquier will continue to "work on strategic issues relating to international markets" in the balance of 1992, J&J said. Under Dupasquier's leadership, consumer product sales in Canada, Europe, Asia and Africa grew in 1991. The gains were offset by "expected" decreases in the dollar value of sales in Brazil, resulting in flat 1991 international sales. During Dupasquier's three-year stint heading the consumer products sector, the group was consolidated and the baby products, dental care and health care subdivisions were merged. J&J expanded its skin care business during Dupasquier's tenure, acquiring Revlon's Clean & Clear skin care brand and revamping its Purpose brand. Like Larson, Dupasquier moved to head of the consumer sector from the post of group chairman with responsibility for feminine hygiene products. Dupasquier joined J&J in 1985. Previously, he was president of the dairy products division of the European company BSN-Gervais-Danone.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel